Unknown

Dataset Information

0

Simultaneous LC-ESI-MS/MS Quantification of Levosimendan and Its Metabolites for Therapeutic Drug Monitoring of Cardiac Surgery Patients.


ABSTRACT: Levosimendan is used in severe chronic cardiac insufficiency, also within the peri-operative setting. Real-life pharmacokinetic data in surgical patients is lacking, making therapeutic drug monitoring (TDM) of levosimendan, its pharmacologically active metabolite OR-1896, and its intermediate OR-1855 important. A simultaneous highly sensitive quantification of levosimendan and its metabolites in small-volume samples has not yet been described. Here, levosimendan (LLOQ 0.450 nM), OR-1896, and OR-1855 (LLOQ both 1.0 nM) were successfully quantified by LC-ESI-MS/MS after liquid-liquid extraction in 300 µL of blood. A short C8 column under reversed-phase conditions enabled simultaneous and fast quantification of levosimendan in the negative and the metabolites in the positive ionization mode in a single run within 2 min. Interestingly and unexpectedly, constitutional isomers of levosimendan metabolites with identical mass transitions and similar retention times were observed in surgical patients' samples, which we identified as the metamizole metabolites 4-aminoantipyrine and 4-acetamidoantipyrine. A longer C8 column and a modified mobile phase enabled selective quantification of all analytes in a single run within 7 min. We developed, validated, and applied highly sensitive LC-ESI-MS/MS methods for simultaneous quantification of levosimendan and its metabolites, enabling efficient TDM of cardiac surgery patients even with additional metamizole administration.

SUBMITTER: Kipka H 

PROVIDER: S-EPMC9319272 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Simultaneous LC-ESI-MS/MS Quantification of Levosimendan and Its Metabolites for Therapeutic Drug Monitoring of Cardiac Surgery Patients.

Kipka Hannah H   Tomasi Roland R   Hübner Max M   Liebchen Uwe U   Hagl Christian C   Wanner Klaus T KT   Mannell Hanna H   Höfner Georg G  

Pharmaceutics 20220712 7


Levosimendan is used in severe chronic cardiac insufficiency, also within the peri-operative setting. Real-life pharmacokinetic data in surgical patients is lacking, making therapeutic drug monitoring (TDM) of levosimendan, its pharmacologically active metabolite OR-1896, and its intermediate OR-1855 important. A simultaneous highly sensitive quantification of levosimendan and its metabolites in small-volume samples has not yet been described. Here, levosimendan (LLOQ 0.450 nM), OR-1896, and OR-  ...[more]

Similar Datasets

| S-EPMC4286417 | biostudies-literature
| S-EPMC2975728 | biostudies-literature
| S-EPMC6358189 | biostudies-literature
| S-EPMC9756784 | biostudies-literature
| S-EPMC9600761 | biostudies-literature
| S-EPMC11664113 | biostudies-literature
| S-EPMC6446716 | biostudies-literature
| S-EPMC7987214 | biostudies-literature
| S-EPMC4511363 | biostudies-literature
| S-EPMC8044036 | biostudies-literature